Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Stephens

Showing results (291-300 of 933) with videos related to

Pageof 94
Sort By:
British Journal of Cancer|December 1, 1993
A simulated sequential analysis based on data from two MRC trialsA N Donaldson, J Whitehead, R Stephens, et al.
European Journal of Biochemistry|May 17, 1982
Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virusL Skriver, L S Nielsen, R Stephens, et al.
Proceedings (Baylor University. Medical Center)|July 20, 2007
Gelatinous bone marrow in an HIV-positive patientJeffrey S Stroup, Johnny R Stephens, Damon L Baker
The Biochemical Journal|December 1, 1991
Multiple isomers of inositol pentakisphosphate in Epstein-Barr-virus- transformed (T5-1) B-lymphocytes. Identification of inositol 1,3,4,5,6-pentakisphosphate, D-inositol 1,2,4,5,6-pentakisphosphate and L-inositol 1,2,4,5,6-pentakisphosphateF M McConnell, L R Stephens, S B Shears
Current Pharmaceutical Design|March 7, 2006
Current HIV treatment guidelines--an overviewR C Rathbun, S M Lockhart, J R Stephens
The Biochemical Journal|July 1, 1990
Agonist-stimulated inositol phosphate metabolism in avian erythrocytesL R Stephens, C P Berrie, R F Irvine
Nature|May 2, 1991
Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophilsL R Stephens, K T Hughes, R F Irvine
Vision Research|January 1, 1982
A failure to observe negative preference in infant acuity testingM S Banks, B R Stephens, J L Dannemiller
Cancer Treatment Reports|March 1, 1981
Therapy for advanced colorectal cancer with a combination of 5-FU and anguidine: a Southwest Oncology Group StudyW Goodwin, R Stephens, J D McCracken, et al.
Seminars in Oncology|December 1, 1982
Ifosfamide in the management of malignant melanoma: a Southwest Oncology Group Phase II StudyJ J Costanzi, R Stephens, R O'Bryan, et al.
Pageof 94

Showing results (291-300 of 933) with videos related to

Sort By:
Pageof 94
British Journal of Cancer|December 1, 1993
A simulated sequential analysis based on data from two MRC trialsA N Donaldson, J Whitehead, R Stephens, et al.
European Journal of Biochemistry|May 17, 1982
Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virusL Skriver, L S Nielsen, R Stephens, et al.
Proceedings (Baylor University. Medical Center)|July 20, 2007
Gelatinous bone marrow in an HIV-positive patientJeffrey S Stroup, Johnny R Stephens, Damon L Baker
The Biochemical Journal|December 1, 1991
Multiple isomers of inositol pentakisphosphate in Epstein-Barr-virus- transformed (T5-1) B-lymphocytes. Identification of inositol 1,3,4,5,6-pentakisphosphate, D-inositol 1,2,4,5,6-pentakisphosphate and L-inositol 1,2,4,5,6-pentakisphosphateF M McConnell, L R Stephens, S B Shears
Current Pharmaceutical Design|March 7, 2006
Current HIV treatment guidelines--an overviewR C Rathbun, S M Lockhart, J R Stephens
The Biochemical Journal|July 1, 1990
Agonist-stimulated inositol phosphate metabolism in avian erythrocytesL R Stephens, C P Berrie, R F Irvine
Nature|May 2, 1991
Pathway of phosphatidylinositol(3,4,5)-trisphosphate synthesis in activated neutrophilsL R Stephens, K T Hughes, R F Irvine
Vision Research|January 1, 1982
A failure to observe negative preference in infant acuity testingM S Banks, B R Stephens, J L Dannemiller
Cancer Treatment Reports|March 1, 1981
Therapy for advanced colorectal cancer with a combination of 5-FU and anguidine: a Southwest Oncology Group StudyW Goodwin, R Stephens, J D McCracken, et al.
Seminars in Oncology|December 1, 1982
Ifosfamide in the management of malignant melanoma: a Southwest Oncology Group Phase II StudyJ J Costanzi, R Stephens, R O'Bryan, et al.
Pageof 94